Exercise on Expression of Heat Shock Protein 70 in Arterial Risk (NCT04743128) | Clinical Trial Compass
CompletedNot Applicable
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk
Mexico32 participantsStarted 2019-06-03
Plain-language summary
Introduction: Atherosclerotic Peripheral Arterial Disease (PAD) is the leading cause of mortality in the western world. To maintain homeostasis of the vessel wall, vascular cells produce a high level of heat shock proteins (HSP), among which is Hsp70, to stimulate innate immunity and face stress.
Methods: This is a clinical trial where 260 individuals were evaluated by a screening test employing the Ankle-Arm Index (ABI), 220 of them were not within risk value (0.91 to 0.99 mmHg). In the clinical trial, 32 individuals were included. A control group and an experimental group were formed. Aerobic exercise intervention was performed for 12 weeks. The level of Hsp70 was evaluated, physical and clinical measurements were applied at the beginning and at the end of the trial.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Individuals who attended the internal medicine service of the "Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado de Puebla" (ISSSTEP) Hospital were invited to participate voluntarily, from February to September of 2019. In order to detect people at risk of PAD, the measurement of the ABI was done. The measure was taken after 10 minutes of resting. The measure was taken in the four extremities to obtain systolic BP of the posterior tibial artery and brachial artery. The cut point to enter the study was between 0.91 and 0.99 mmHg. The informed consent was signed by all the individuals.
Inclusion criteria
* ABI cut point from 0.91 to 0.99
* Age, from 40 to 75 years old
* Both genders
Exclusion criteria
* Unable to perform Bruce's stress test
* Presence of fractures or sprains in the last 3 months
* Diagnosis of diabetes, heart disease, angina pectoris or heart attack
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Impact of exercise on expression of Hsp70 in individuals at risk of peripheral arterial disease
Timeframe: 12 weeks
Trial details
NCT IDNCT04743128
SponsorUniversidad Popular Autónoma del Estado de Puebla